TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04138303

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Protocol
Description: The exercise protocol consists of a nine-week progressive intense-conditioning program involving six consecutive days (Monday-Saturday) of one-hour exercises and one-day rest weekly for a total of 54 days of exercise. Exercises are performed in person as a group with other participating subjects and lead by certified instructors. Exercises will involve a variety of activities ranging from running, cycling, whole-body functional movements, power movements, and open-chain weight lifting with barbells and resistance bands.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Protocol
Description: The exercise protocol consists of a nine-week progressive intense-conditioning program involving six consecutive days (Monday-Saturday) of one-hour exercises and one-day rest weekly for a total of 54 days of exercise. Exercises are performed in person as a group with other participating subjects and lead by certified instructors. Exercises will involve a variety of activities ranging from running, cycling, whole-body functional movements, power movements, and open-chain weight lifting with barbells and resistance bands.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Protocol
Description: The exercise protocol consists of a nine-week progressive intense-conditioning program involving six consecutive days (Monday-Saturday) of one-hour exercises and one-day rest weekly for a total of 54 days of exercise. Exercises are performed in person as a group with other participating subjects and lead by certified instructors. Exercises will involve a variety of activities ranging from running, cycling, whole-body functional movements, power movements, and open-chain weight lifting with barbells and resistance bands.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Calorie-Restrictive Low Carbohydrate Diet (CR-LC)
Description: Consists of weekly nutrition plans, counseling and monitoring by on-site registered dietitians and nutritionists for nine weeks. CR-LC consists of caloric and macronutrient restrictions. Caloric restrictions involves a 40% deficit from calculated total daily energy expenditure. Macronutrient restriction involves a high protein, low carbohydrate diet (35% protein, 25% carbohydrate and 40% fat).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ancestral Diet (AD)
Description: Consists of weekly nutrition plans, counseling and monitoring by on-site registered dietitians and nutritionists for nine weeks. AD consists of consuming only whole foods and avoiding processed foods. Emphasis will be on food quality with no caloric or macronutrient restrictions.
Study: NCT02210403

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial direct current stimulation (tDCS)
Study: NCT02258256

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sphygmo
Description: A team of engineers from Rice University has recently developed Sphygmo, an ambulatory, low-cost blood pressure monitor for use in the diagnosis and management of pre-eclampsia in low-resource hospitals
Study: NCT02557607

Intervention type: DEVICE
Group type: OTHER
Intervention: MRI
Description: An analysis of the three sessions MRI performed systematically within the first 14 days of the start of symptoms revealing the HSA will be
Study: NCT01834053

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: autologous Stem Cell
Description: Intrathecal transplantation of autologous 100 millions Stem cells{MNCs } per dose'
Study: NCT01963039

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: percutaneous vertebroplasty
Description: Using fluoroscopic guidance, the practitioner infiltrates the skin and subcutaneous tissues overlying the pedicle of the target vertebra or vertebrae with 1% lidocaine and infiltrates the periosteum of the pedicles with 0.25% bupivacaine (marcaine. For the vertebroplasty procedure, 11-gauge or 13-gauge needles are passed into the central aspect of the target vertebra or vertebrae. Bone cement is prepared on the bench and injected under constant fluoroscopy into the vertebral body. Injection is stopped when the PMMA reaches the posterior aspect of the vertebral body or leaks into an extraosseous space, such as the intervertebral disk or an epidural or paravertebral vein.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham procedure
Description: Using fluoroscopic guidance, the practitioner infiltrates the skin and subcutaneous tissues overlying the pedicle of the target vertebra or vertebrae with 1% lidocaine and infiltrates the periosteum of the pedicles with 0.25% bupivacaine (marcaine). During the sham intervention, verbal and physical cues, such as pressure on the patient's back, are given, and the methacrylate monomer (PMMA) is opened to simulate the odor associated with mixing of cement, but the needle is not placed and cement is not injected.
Study: NCT04073147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax per os

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax per os

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax per os

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: ObintuzumabIV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: ObintuzumabIV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: ObintuzumabIV
Study: NCT04835948

Intervention type: DRUG
Intervention: single dose of Anti-thymocyte globulin
Description: Used anti-thymocyte globulin (ATG) in a single dose of 3 mg/kg for immunosuppression induction in the immediate postoperative period
Study: NCT01245790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fostamatinib
Description: Oral tablets, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fostamatinib
Description: Oral tablets, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fostamatinib
Description: Oral tablets, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fostamatinib
Description: Oral tablets, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fostamatinib
Description: Oral tablets, single dose
Study: NCT04111770

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IVUS guided Percutaneous Coronary Intervention
Description: Pre-procedural IVUS will be used to determine lesion characteristics and post-procedural IVUS to confirm correct implantation of stent.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: QCA guided Percutaneous Coronary Intervention
Description: QCA will be used to determine lesion characteristics
Study: NCT00669864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 30
Description: Subcutaneous (under the skin) injection, twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: Tablets, 1000 - 2000 mg daily
Study: NCT00323947

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Extended Release Methylphenidate (OROS-Methylphenidate)
Description: Participants will first take either immediate release MPH or placebo A for 1 day. On Day 2 of treatment, participants assigned to receive XR-MPH will begin taking it, and participants assigned to receive placebo will switch to placebo B. This treatment phase will continue for 6 days to 4 weeks, depending on weight, and will then be followed by a 1-week medication washout period. Target dose depends on the weight of the participant. Possible dose forms include 18, 36, 54 mg OROS-MPH.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Extended Release Methylphenidate (OROS-Methylphenidate)
Description: Participants will first take either immediate release MPH or placebo A for 1 day. On Day 2 of treatment, participants assigned to receive XR-MPH will begin taking it, and participants assigned to receive placebo will switch to placebo B. This treatment phase will continue for 6 days to 4 weeks, depending on weight, and will then be followed by a 1-week medication washout period. Target dose depends on the weight of the participant. Possible dose forms include 18, 36, 54 mg OROS-MPH.
Study: NCT02705053

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CGM and Insulin Pump
Description: Dexcom G4 Platinum CGM with Share AP Receiver Roche Accu-Chek insulin pump.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed-Loop Control System
Description: The devices that will be used in the Closed-Loop Control System include the following components:~DiAs - a smart-phone medical platform; Dexcom G4 Platinum connected to DiAs via Bluetooth CGM receiver; Roche Accu-Chek insulin pump connected to DiAs via wireless Bluetooth; Remote Monitoring Server connected to DiAs via 3G or local Wi-Fi network, and Zone-MPC and HMS algorithms running on DiAs (MPC and HMS)
Study: NCT03130764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: 1500 mg, IV over 1 hour Every 4 weeks for 1 year

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: 75 mg, IV over 1 hour Every 4 weeks for 4 doses
Study: NCT02647983

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperpolarized Pyruvate (13C) Injection
Description: Hyperpolarized Pyruvate (13C) Injection is a MRI contrast agent.
Study: NCT01517256

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Living Everyday Above-and-beyond Pain (LEAP)
Description: 8-week multidisciplinary group therapy aiming consisting of education about the nature of chronic pain, pacing and goal setting, mindfulness medication techniques, cognitive reflections on beliefs, impulses and obsessions, physical activation, and medication management.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Wait-listed
Description: Patients are wait-listed while awaiting participation to the LEAP program.
Study: NCT03189706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 50mg/m\^2/day IV will be administered from day 1-5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: (given concurrently with Irinotecan) 150mg/m\^2/day orally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hu3F8
Description: 2.25mg/kg IV will be administered on days 2, 4, 8 and 10

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: 250mcg/m2/day SC will be administered on days 6-10
Study: NCT01238848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypertonic saline
Description: 3 cc nebulized hypertonic saline + albuterol 0.25 mg/kg/day, four times a day (QID), 5 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: 3 cc nebulized normal saline + albuterol 0.25 mg/kg/day, four times a day (QID), 5 days
Study: NCT03213210

Intervention type: DEVICE
Group type: OTHER
Intervention: easy-graft CLASSIC (beta-Tricalcium Phosphate)
Description: easy-graft will be grafted to the bone defect supporting a dental implant and covered by polylactide membrane to facilitate regeneration of new bone and healthy attachment to stabilize the dental implant.
Study: NCT00449878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liprotamase
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study: NCT02344654

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine green

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Near-infrared illumination
Description: To see the fluorescence from indocyanine green

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Urografin

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: X-ray
Study: NCT01546857

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal Saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gapabentin
Description: 400mg orally at 9pm day of surgery and the first evening post operatively.
Study: NCT02181465

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: G17DT

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: G17DT
Study: NCT02197117

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Remote ischemic conditioning

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Control
Study: NCT05003375

Intervention type: BEHAVIORAL
Intervention: High-challenging cognitive protocol to provoke stress and (cognitive) fatigue
Description: Baseline measurement is done in two parts: 1) resting for five minutes (no talking, no movement) and 2) speaking at normal pace (2 minutes).~This is immediately followed by a measurement of the physiological response variables during the testing, in which the following protocol is performed in the order presented: 1) SDMT-NBack task-SDMT\*-NBacktask\*\*, 2) NBack task-SDMT-NBack task-SDMT. Participants will run either sequence to check for effects of the previous testing. During the conduct of the study, it will be ensured that half of the participants in each group followed Sequence 1 and the other half of the group followed Sequence 2.~During all these measurements, the participant will sit at a table with a computer on which the tests are performed.~\*SDMT: Symbol Digit Modalities Test: see description in outcome measures~\*\*N-Back Task: see description in outcome measures

Intervention type: BEHAVIORAL
Intervention: High-challenging cognitive protocol to provoke stress and (cognitive) fatigue
Description: Baseline measurement is done in two parts: 1) resting for five minutes (no talking, no movement) and 2) speaking at normal pace (2 minutes).~This is immediately followed by a measurement of the physiological response variables during the testing, in which the following protocol is performed in the order presented: 1) SDMT-NBack task-SDMT\*-NBacktask\*\*, 2) NBack task-SDMT-NBack task-SDMT. Participants will run either sequence to check for effects of the previous testing. During the conduct of the study, it will be ensured that half of the participants in each group followed Sequence 1 and the other half of the group followed Sequence 2.~During all these measurements, the participant will sit at a table with a computer on which the tests are performed.~\*SDMT: Symbol Digit Modalities Test: see description in outcome measures~\*\*N-Back Task: see description in outcome measures
Study: NCT04630665

Intervention type: OTHER
Group type: OTHER
Intervention: immediate implant placement
Description: immediate implant placement in thin and thick buccal bony plates

Intervention type: OTHER
Group type: OTHER
Intervention: immediate implant placement
Description: immediate implant placement in thin and thick buccal bony plates
Study: NCT04442542

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Respiratory muscle training 1 (Experimental Group)
Description: The participant must perform a series of exercises that will be the same for the two groups in this investigation. In addition to the exercises, this group will use the incentive inspirometer device with a new method created by the main author called the Method JaPer.~For the method JaPer, the participant sits and holds the device. Then put the mouthpiece of the inspirometer in the mouth. Be sure to make a good seal on the mouthpiece with your lips. And exhale normally until you run out of air. And after that, inhale slowly as much as possible. This maximum value will be taken as an indicative parameter of its maximum inspiratory capacity and 50 and 80% for 1 set of 10 repetitions at 50% of their maximum value, 2 sets of 10 repetitions at 60% of its maximum capacity and ends with 1 series at 80% of its maximum capacity. It is highlighted that in each series before finishing and without stopping to rest, the participant must do 5 repetitions at 100% maximum capacity

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Respiratory muscle training 2 (Control Group)
Description: Training of respiratory muscles under the protocol of conventional use. Which is that the participant sits and holds the device. Then put the mouthpiece of the inspirometer in the mouth. Be sure to make a good seal on the mouthpiece with your lips. And exhale (exhale) normally until you run out of air. And after that, inhale (inspire) slowly as much as possible. Repeat 10 times and use these indications for 3 sets. In addition, participants must perform the same breathing exercises that are identical for experimental group.
Study: NCT02090426

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Link2Care
Study: NCT02462148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Used in nerve block mixture

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Used in nerve block mixture

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Used in nerve block mixture

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Used in nerve block mixture

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacaine
Description: Used in nerve block mixture

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine
Description: Used in nerve block mixture

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine
Description: Used in nerve block mixture

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Epinephrine
Description: Used in nerve block mixture

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Saphenous Peripheral Nerve Block
Description: Peripheral nerve block.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Saphenous Peripheral Nerve Block
Description: Peripheral nerve block.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Saphenous Peripheral Nerve Block
Description: Peripheral nerve block.
Study: NCT02418572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone gel
Description: Patients will receive once daily application of 0.55 gr testosterone gel-TTG (GROUP A) (Testosterone gel 1%; Laboratories Besins International, Paris, France) with a 5.5 mg/d nominal delivery rate of testosterone starting from day 1 or 2 of the following menstrual cycle, for approximately 65 days.~The application will be administered in the morning by the patient onto clean dry healthy skin over external surface of the thighs. The gel will be simply spread on the skin gently as a thin layer.~TTG will start on the day of enrollment and will continue until patients' menstruation (28-30 days). Daily administration of TTG or placebo will continue for 35 days (21days until the initial of downregulation with triptorelin and for 14 more days until the initiation of ovarian stimulation with HP-hMG). Ovarian stimulation will commence the day after last testosterone gel application. (GROUP A)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel
Description: Patients will receive once daily application of 0.55 gr of placebo gel from day 1 or 2 of the following menstrual cycle, for approximately 65 days.~The application will be administered in the morning by the patient onto clean dry healthy skin over external surface of the thighs. The gel will be simply spread on the skin gently as a thin layer.~Placebo gel will start on the day of enrollment and will continue until patients' menstruation (28-30 days). Daily administration of placebo gel will continue for 35 days (21 days until the initial of downregulation with triptorelin and for 14 more days until the initiation of ovarian stimulation with HP-hMG
Study: NCT01911715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDV3100
Description: Oral
Study: NCT00883779

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: po on days 15-28 of each 4 week cycle until disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum chemotherapy (cisplatin or carboplatin)
Description: cisplatin --75mg/m2 oon day 1 of each 4 week cycle for 6 cycles or carboplatin--5xAUC on day 1 of each 4 week cycle for 6 cycles

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Platinum chemotherapy (cisplatin or carboplatin)
Description: cisplatin --75mg/m2 oon day 1 of each 4 week cycle for 6 cycles or carboplatin--5xAUC on day 1 of each 4 week cycle for 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib [Tarceva]
Description: 150mg po on days 15-28 of each 4 week cycle until disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: 1250mg/m2 iv on days 1 and 8 of each 4 week cycle for 6 cycles

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: gemcitabine
Description: 1250mg/m2 iv on days 1 and 8 of each 4 week cycle for 6 cycles
Study: NCT04503746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALH-L1005 600mg/day
Description: ALH-L1005 300mg 2 tablet and placebo 2 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALH-L1005 1,200mg/day
Description: ALH-L1005 300mg 4 tablet
Study: NCT03117231

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Transcranial Direct Current Stimulation (tDCS)
Description: Subjects will undergo 15 sessions of tDCS stimulation, 1x per day at 20 minutes per session, of up to 2mA. During active stimulation, the current will be active for the full 20 minutes.
Study: NCT04503746

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 4 tablet
Study: NCT03313869

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: XXS-2A + Omega-3 + Vitamin E + Selenium
Description: Micronutrient cocktail supplementation with 560,7 mg/ day of polyphenols (3 pills/day), 2,1 g/day of omega-3 fatty-acids (3 pills/day), 168 mg/day of vitamin E and 80µg/day of selenium (1 pill/day)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: control diet
Description: habitual diet to be followed
Study: NCT03986996

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amoxicillin, metronidazole and doxycycline
Description: antibiotics: Patient weight 30-50 kg Patient weight \> 50 kg Tetracycline 50 mg X 2 Day X 2 weeks 100 mg X 2 Day X 2 weeks Amoxicillin 750 mg X 2 Day X 2 weeks 750 mg X 2 Day X 2 weeks Metronidazole 250 mg X 2 Day X 2 weeks 375 mg X 2 Day X 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amoxicillin and doxycyclin
Description: antibiotics: Patient weight 30-50 kg Patient weight \> 50 kg Tetracycline 50 mg X 2 Day X 2 weeks 100 mg X 2 Day X 2 weeks Amoxicillin 750 mg X 2 Day X 2 weeks 750 mg X 2 Day X 2 weeks
Study: NCT00872963

Intervention type: BIOLOGICAL
Intervention: RTS,S/AS01E
Description: 0.5MLS of RTS,S/AS01E at 0,1,2 monthly schedule 0.5mls Rabies vaccine at 0,1,2 monthly schedule

Intervention type: BIOLOGICAL
Intervention: RTS,S/AS01E
Description: 0.5MLS of RTS,S/AS01E at 0,1,2 monthly schedule 0.5mls Rabies vaccine at 0,1,2 monthly schedule